Biofrontera Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Biofrontera reported Q3 2026 net product revenue of $9.1M (+29.8% YoY) and nine-month revenue of $31.2M (+26.6% YoY). On September 9, 2026, the FDA approved Ameluz for superficial basal cell carcinoma (sBCC), the first PDT approved for cancerous skin tumors. On September 14, 2026, U.S. Customs and Border Protection ruled the redesigned RhodoLED XL-C lamp complies with import requirements, ending the ITC exclusion order. Gross margin improved to 74.4% in Q3 (vs. 70.7% prior year) due to lower Ameluz cost structure from the October 2025 strategic transaction with Biofrontera AG. Net loss narrowed to $6.4M for Q3 (vs. $6.6M prior year) and $11.8M for nine months (vs. $16.2M prior year). Cash declined to $3.2M as of September 30, 2026 (from $6.4M at year-end 2025); convertible notes of $4.7M mature November 2027.
Why this rating
FDA sBCC approval + ITC clearance remove regulatory/legal headwinds; 30% revenue growth and margin expansion are material for ~$7M market-cap company. Cash runway and debt maturity present refinancing risk.
Tradability signal
NO TRADE
No trade: price $0.00 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.00 | +10 min · unknown $0.00 ▲ 0.00% | +30 min · unknown $0.00 ▲ 0.00% | +1 hr · unknown $0.00 ▲ 0.00% | +4 hrs · unknown $0.00 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.